Radioactive cancer drugs face access bottleneck despite clinical promise

The article highlights the growing use of radiopharmaceuticals for cancer diagnosis and treatment, but notes a critical bottleneck in production and distribution that limits patient access. The specific nature of the bottleneck—whether regulatory, supply-chain, or infrastructure—is not detailed in the provided text. This matters because radiopharmaceuticals are a rapidly expanding oncology tool, and access constraints could delay care for patients globally.